Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)–positive adult B-ALL in 2018, ...
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...
Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results